NCCN Guidelines for Patients® | Myeloproliferative Neoplasms

72 NCCN Guidelines for Patients ® : Myeloproliferative Neoplasms, 2018 Index Index 2 nd opinion 60 acquired von Willebrand disease (VWD) 20, 24, 27–28, 38–39 allogeneic hemopoietic cell transplant (HCT) 44, 48–49, 53 AML (acute myeloid leukemia) 12, 26, 28–29, 37, 39, 44, 46, 51–53, 56 anemia 16, 26, 43–44, 48–50, 52 anticoagulant 24, 34 aspirin 23–25, 27–30, 33, 35, 39–40 blood tests 15–16, 20, 22, 27, 30, 32, 38, 40, 52 bone marrow exam 17, 20 CALR mutations 14, 19 chemotherapy 26, 49, 51, 53 chronic myeloid leukemia (CML) 18 clinical trial 29–30, 39–40, 44–45, 50, 53, 57 coagulation tests 14, 20, 24 complete blood count (CBC) 14–15 cytoreductive treatment 23, 26–28, 30, 33, 37–40, 51, 53 Dynamic International Prognostic Scoring System (DIPSS)-PLUS 44 essential thrombocythemia (ET) 6, 10, 12, 19–20, 22–28, 30, 42–43, 53 genetic tests 18, 20 human leukocyte antigen (HLA) typing 14, 19–20, 49 JAK2 mutations 14, 18–19, 23, 33 kinase inhibitor 47 medical history 14–15, 20 monitoring 27, 38, 52 MPL mutations 19, 22, 43 myelodysplastic syndromes (MDS) 8, 10, 12, 22, 43 Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) 14, 27, 38, 44, 52 NCCN Member Institutions 71 NCCN Panel Members 70 observation 23, 25, 44, 53 phlebotomy 33, 36, 38, 40 plateletpheresis 24, 34 polycythemia vera (PV) 10–12, 15–16, 18–20, 32–43, 53 post-ET myelofibrosis 11, 42–43, 53 post-PV myelofibrosis 11, 42–43, 53 primary myelofibrosis (PMF) 10–11, 18–19, 42–43, 48, 51, 53 shared decision–making 55, 61 supportive care 50–53 triple-negative MPN 19

RkJQdWJsaXNoZXIy MTE3MTE1